Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Lacombe

Showing results (51-60 of 118) with videos related to

Pageof 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 8, 2008
Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001)Lothar Bergmann, Steiner Aamdal, Sandrine Marreaud, et al.
European Journal of Cancer (Oxford, England : 1990)|December 20, 2008
Individual patient data analysis to assess modifications to the RECIST criteriaJan Bogaerts, Robert Ford, Dan Sargent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignanciesVéronique Diéras, Jacques Bonneterre, Valérie Laurence, et al.
Annals of Surgery|November 10, 2016
From a Comic Opera to Surcare an Open Letter to Whom Clinical Research in Surgery Is a Concern: Announcing the Launch of SURCARESerge Evrard, Ricardo Audisio, Graeme Poston, et al.
Investigational New Drugs|October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancerChristian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2025
The 2024 State of Science report from the European Organisation for Research and Treatment of Cancer's Radiation Oncology Scientific CouncilDaniel Portik, Denis Lacombe, Corinne Faivre-Finn, et al.
ESMO Open|October 13, 2017
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patientsAnastassia Negrouk, Denis Lacombe, Fatima Cardoso, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2020
The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting reportGillian Thomas, Elizabeth Eisenhauer, Robert G Bristow, et al.
Tumori|November 14, 2019
What could be a cancer mission objective if we join our forces in the fight against cancer?Thierry Philip, Sakari Karjalainen, Francesco De Lorenzo, et al.
Neuro-Oncology|February 1, 2012
A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054)Roy Rampling, Marc Sanson, Thiery Gorlia, et al.
Pageof 12

Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|July 8, 2008
Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001)Lothar Bergmann, Steiner Aamdal, Sandrine Marreaud, et al.
European Journal of Cancer (Oxford, England : 1990)|December 20, 2008
Individual patient data analysis to assess modifications to the RECIST criteriaJan Bogaerts, Robert Ford, Dan Sargent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignanciesVéronique Diéras, Jacques Bonneterre, Valérie Laurence, et al.
Annals of Surgery|November 10, 2016
From a Comic Opera to Surcare an Open Letter to Whom Clinical Research in Surgery Is a Concern: Announcing the Launch of SURCARESerge Evrard, Ricardo Audisio, Graeme Poston, et al.
Investigational New Drugs|October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancerChristian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2025
The 2024 State of Science report from the European Organisation for Research and Treatment of Cancer's Radiation Oncology Scientific CouncilDaniel Portik, Denis Lacombe, Corinne Faivre-Finn, et al.
ESMO Open|October 13, 2017
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patientsAnastassia Negrouk, Denis Lacombe, Fatima Cardoso, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2020
The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting reportGillian Thomas, Elizabeth Eisenhauer, Robert G Bristow, et al.
Tumori|November 14, 2019
What could be a cancer mission objective if we join our forces in the fight against cancer?Thierry Philip, Sakari Karjalainen, Francesco De Lorenzo, et al.
Neuro-Oncology|February 1, 2012
A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054)Roy Rampling, Marc Sanson, Thiery Gorlia, et al.
Pageof 12